Open an account

enGene Therapeutics

ENGN · NASDAQ

$1.67+$0.09 (+5.70%)TodayMarket closed ·
Prev close $1.58

About ENGN

enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. The company is headquartered in Saint-Laurent, Quebec and currently employs 45 full-time employees. The company went IPO on 2021-12-10. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).

Employees
45
Headquarters
Saint-Laurent, Quebec
Listed
Dec 10, 2021
Sector
Health Care
Industry
Biotechnology
Website
engene.com

ENGN key statistics

Market cap
111.92M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
874.16K
Volume
1.12M
Open price
$1.60
High today
$1.72
Low today
$1.59
52 Week high
$12.25
52 Week low
$1.40

enGene Therapeutics (ENGN) at a glance

As of Oct 20, 2026, enGene Therapeutics (ENGN) shares are priced at $1.67, giving the company a market cap of 111.92M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.59 and $1.72. The current price is 5.0% above the day's low and 2.9% below its high.

Volume so far is 1.12M shares, above the average of 874.16K shares a day.

Over the past year enGene Therapeutics has ranged from $1.40 to $12.25, and now sits 2% of the way up that range.

enGene Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q3 FY26 it reported -$0.47 per share against an estimate of -$0.4386.

The average analyst price target is $7.80, 367.2% above the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

45%of 11 analyst ratings say Buy
  • Buy45.5%
  • Hold45.5%
  • Sell9.1%
Price target · 12 analystsAvg $7.80
Low
$2.02
Now
$1.67
High
$28.35

ENGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 15.0% on average.

  1. Q4 FY24: reported -$0.34 per share against an estimate of -$0.3852
  2. Q1 FY25: reported -$0.48 per share against an estimate of -$0.3787
  3. Q2 FY25: reported -$0.51 per share against an estimate of -$0.5081
  4. Q3 FY25: reported -$0.57 per share against an estimate of -$0.5111
  5. Q4 FY25: reported -$0.73 per share against an estimate of -$0.5796
  6. Q1 FY26: reported -$0.44 per share against an estimate of -$0.571
  7. Q2 FY26: reported -$0.43 per share against an estimate of -$0.4795
  8. Q3 FY26: reported -$0.47 per share against an estimate of -$0.4386

ENGN news

  • Press releaseBusiness Wire

    enGene to Host KOL Webinar on October 15, 2026

  • Press releaseBusiness Wire

    enGene Reports Third Quarter 2026 Financial Results and Provides Business Update

  • Press releaseBusiness Wire

    enGene to Participate in Upcoming Investor Conferences

  • Press releaseBusiness Wire

    enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

  • Press releaseBusiness Wire

    enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

  • Press releaseBusiness Wire

    enGene Reports Second Quarter 2026 Financial Results and Provides Business Update

  • Press releasePRNewswire

    ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN

Similar companies

Companies in the same industry as enGene Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.